Browsing by Author Pujade-Lauraine, Eric

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 11 of 11
Issue DateTitleAuthor(s)Citation
2017Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: Exploratory analyses of the AURELIA trialDavies, Lucy; Gebski, Val; Gibbs, Emma; Lee, C.; Veillard, Anne-Sophie; Bamias, A; Bloemendal, H; Dimopoulos, M; Floquet, A.; Kosse, J; Lykka, M; Mirza, Mansoor Raza; Pujade-Lauraine, Eric; santaballa, A; Tabaro, G; Vergote, I; Zagouri, F; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreBevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: Exploratory analyses of the AURELIA trial, Annals of Oncology, vol.28, 8, 2017,pp 1842-1848
2012Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trialBrown, Christopher; De Rauglaudre, G; Elit, Laurie; Ferrero, A.; Gladieff, Laurence; Helland, H; Lorusso, D; Mahner, S; Pujade-Lauraine, Eric; Reed, N; Reinthaller, A; Siena, Salvatore; Vasey, P; NH&MRC Clinical Trials CentreCarboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial, Annals of Oncology, vol.23, 5, 2012,pp 1185-1189
2011Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancerBrown, Christopher; Gebski, Val; Gurney, Howard; Lee, Chee; Lord, Sarah (Sally); Simes, Robert John; Bacon, M; Donadello, Nicoletta; Friedlander, Michael; Maenpaa, J; Meier, W; Petru, E; Pujade-Lauraine, Eric; Reed, N; Sorio, R; Tulunay, G; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCarboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer, British Journal of Cancer, vol.105, 3, 2011,pp 360-365
2011Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer.Brown, Christopher; Gebski, Val; Lee, Chee; Lord, Sarah (Sally); Simes, Robert John; Delva, Remy; Donadello, Nicoletta; Friedlander, Michael L.; Georgoulopoulos, Alexander; Mirza, Mansoor Raza; Pignata, Sandro; Pujade-Lauraine, Eric; Schmalfeldt, Barbara; Southier, Philippe; Vergote, Ignace; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreEarly Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer., Journal of the National Cancer Institute, vol.103, 17, 2011,pp 1338-1342
2015Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trialGebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Ferrero, A.; Friedlander, Michael; Grunewald, Tami; Hardy-Bessard, Anne Claire; Harter, Philipp; Heywood, M; Pujade-Lauraine, Eric; Scambia, G; Schauer, C; Sehouli, Jalid; Vergote, Ignace; Woie, Kathrine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreImpact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial, Gynecologic Oncology, vol.136, 1, 2015,pp 18-24
2017Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialGebski, Val; et al, Various; Huzarski, Tomasz; Korach, Jacob; Ledermann, Jonathan; Oza, Amit M; Penson, Richard; Pignata, Sandro; Poveda, Andres; Pujade-Lauraine, Eric; Selle, Frederic; NH&MRC Clinical Trials CentreOlaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial, The Lancet Oncology, vol.18, 9, 2017,pp 1274-1284
2011Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-studyBrown, Christopher; Veillard, Anne-Sophie; Buck, M; Dorum, Anne; Elit, Laurie; Floquet, A.; Kaminsky, M; Kimmig, R; Kurtz, J; Petru, E; Pujade-Lauraine, Eric; Reed, N; Scambia, G; Varsellona, N; Medicine Faculty Office; School of Public Health: NH&MRC Clinical Trials CentreOvarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study, Annals of Oncology, vol.22, 11, 2011,pp 2417-2423
2010Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late RelapseBrown, Christopher; Gebski, Val; Aavall-Lundqvist, Elisabeth; du Bois, Andreas; Ferrero, Annamaria; Heywood, Mark; Jackisch, Christian; Joly, Florence; Kristensen, Gunnar; Le Fur, Nathalie; Lortholary, Alain; Pignata, Sandro; Pujade-Lauraine, Eric; Sehouli, Jalid; Vasey, Paul A.; Vergote, Ignace; Volgger, Birgit; Wagner, Uwe; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentrePegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse, Journal of Clinical Oncology, vol.28, 20,pp 3323-3329
2011A phase 3 trial of bevacizumab in ovarian cancerBeale, Philip; Carey, Mark; Cervantes, Andres; Collinson, Fiona; du Bois, Andreas; Essapen, Sharadah; Gourley, Charlie; Kimmig, R; Kristensen, Gunnar; Kurzeder, Christian; Ledermann, Jonathan; Lemenin, Arto; Lortholary, Alain; Mirza, Mansoor Raza; Oza, Amit; Parmar, M. K. B.; Perren, Timothy; Pfisterer, J.; Plante, Marie; Pujade-Lauraine, Eric; Qian, Wendi; Sehouli, Jalid; Selle, Frederic; Stahle, Anne; Stark, Dan; Swart, Ann Marie; Central Clinical School: MedicineA phase 3 trial of bevacizumab in ovarian cancer, New England Journal of Medicine, vol.365, 26, 2011,pp 2484-2496
2011Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancerBrown, Christopher; Gebski, Val; Lee, Chee; Lord, Sarah (Sally); Simes, Robert John; Angleitner-Boubenizek, L.; Bentley, J.; Bourgeois, H.; Burges, A.; Ferrero, A.; Friedlander, Michael; Hirte, H.; Hogberg, T.; Parma, G.; Pfisterer, J.; Pisano, C.; Plante, M.; Pujade-Lauraine, Eric; Richter, B.; Vergote, Ignace; Wagner, U.; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentrePrognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer, British Journal of Cancer, vol.105, 8, 2011,pp 1144-1150
2017Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudyAsher, Rebecca; Davies, Lucy; Gebski, Val; Gibbs, Emma; King, Madeleine; Lee, Chee Khoon; Roncolato, Felicia; Stockler, Martin; Friedlander, Michael; Hilpert, Felix; Pujade-Lauraine, Eric; Wenzel, Lari; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Psychology; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreQuality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy, Annals of Oncology, vol.28, 8, 2017,pp 1849-1855